Abstract 1284P
Background
Lung cancer (LC) is the leading cause of cancer-related death worldwide, and up to five times more likely to occur in smokers with chronic obstructive pulmonary disease (COPD) than those with normal lung function. In this study, we investigated the overlap between patients registered with COPD and patients examined on suspicion of LC over a 10-year period in the Region of Southern Denmark.
Methods
The National Registry of COPD and the Danish LC Registry delivered data on patients with COPD and LC respectively. The cohort referred for LC diagnostics was defined by assigned classification codes provided from the Health Care Classification System.
Results
During the study period, 25,647 patients were registered with COPD during hospitalizations, or from outpatient clinics. Among these, 5.030 patients (20%) were referred to LC diagnostics, and 1,551 were diagnosed with LC. This corresponds to a LC incidence of 6% among all patients with COPD, and 31% among COPD patients referred for LC diagnostics. COPD patients referred for LC diagnostics were generally more affected by COPD compared to the group of not referred for LC diagnostics. Referred patients collected more COPD related medication (6 of 7 medicaments), performed worse in terms of lung function (FEV1% 48% vs. 50%), suffered from a higher grade of dyspnea (71% vs. 57% MRC 3-5) and experiences a higher rate of exacerbations (42% vs. 31% with 2-3 exacerbations) compared to COPD patients not referred to LC diagnostics (p<0.05 for all). Among all patients who underwent LC diagnostics, COPD patients displayed a higher prevalence of LC compared to the non-COPD patients (31% vs. 29%, p<0.005). LC patients with COPD were more likely to be stage I-II compared to the non-COPD LC population (39% vs. 24%, p<0.05).
Conclusions
This study reveals a substantial overlap between patients with COPD and patients undergoing LC diagnostics (20%). It suggests that patients more affected by COPD are more likely to undergo LC diagnostics, and LC patients with COPD are more likely to be diagnosed in early stages. It underlines the overrepresentation of LC patients among patients with COPD, and emphasizes the need to address these patients specifically once initiating a screening program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Margrethe Bang Henriksen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
466P - Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
Presenter: Lei Tang
Session: Poster session 04
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04